Keywords
Last Name
Institution

Simon J. Hall

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentUrology
Address5 East 98th Street
6th Floor
New York NY 10029
Phone212-241-4812

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Weissbart SJ, Hall SJ, Fultz BR, Stock JA. The urology match as a prisoner's dilemma: a game theory perspective. Urology. 2013 Oct; 82(4):791-7.
      View in: PubMed
    2. Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology. 2013 Aug; 82(2):410-5.
      View in: PubMed
    3. Mohamed NE, Chaoprang Herrera P, Hudson S, Revenson TA, Lee CT, Quale DZ, Zarcadoolas C, Hall SJ, Diefenbach MA. Muscle invasive bladder cancer: examining survivor burden and unmet needs. J Urol. 2014 Jan; 191(1):48-53.
      View in: PubMed
    4. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, Frenette PS. Autonomic nerve development contributes to prostate cancer progression. Science. 2013 Jul 12; 341(6142):1236361.
      View in: PubMed
    5. Mock S, Leapman M, Stock RG, Hall SJ, Stone NN. Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters. J Urol. 2013 Nov; 190(5):1805-10.
      View in: PubMed
    6. Leapman MS, Hall SJ, Stone NN, Stock RG. Haematuria after prostate brachytherapy. BJU Int. 2013 Jun; 111(8):E319-24.
      View in: PubMed
    7. Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013 Dec; 31(6):1535-9.
      View in: PubMed
    8. Mohamed NE, Diefenbach MA, Goltz HH, Lee CT, Latini D, Kowalkowski M, Philips C, Hassan W, Hall SJ. Muscle invasive bladder cancer: from diagnosis to survivorship. Adv Urol. 2012; 2012:142135.
      View in: PubMed
    9. Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer. 2012 Sep; 10(3):159-63.
      View in: PubMed
    10. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold J, Sonpavde G, Palese MA, Hall SJ, Oh WK, Galsky MD. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World J Urol. 2013 Oct; 31(5):1211-7.
      View in: PubMed
    11. Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012 Jul; 188(1):21-6.
      View in: PubMed
    12. Trindade AJ, Khaitov S, Potack JZ, Hall SJ, Shi Q, DiMaio CJ. Successful EUS-guided FNA through a colonic stent array for diagnosis of an extraluminal pelvic malignancy causing colonic obstruction. Gastrointest Endosc. 2012 Nov; 76(5):1070-2.
      View in: PubMed
    13. Diefenbach MA, Mohamed NE, Butz BP, Bar-Chama N, Stock R, Cesaretti J, Hassan W, Samadi D, Hall SJ. Acceptability and preliminary feasibility of an internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: randomized pilot study. J Med Internet Res. 2012; 14(1):e6.
      View in: PubMed
    14. Phalen A, Akhavan A, Hall SJ. Müllerian remnant malignancy. Urology. 2012 Mar; 79(3):e38-9.
      View in: PubMed
    15. Mohamed NE, Bovbjerg DH, Montgomery GH, Hall SJ, Diefenbach MA. Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer. Urol Oncol. 2012 Nov-Dec; 30(6):804-12.
      View in: PubMed
    16. Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011 Sep; 186(3):877-81.
      View in: PubMed
    17. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011 Jul 1; 17(13):4558-67.
      View in: PubMed
    18. Galsky MD, Hall SJ. Bladder cancer: current management and opportunities for a personalized approach. Mt Sinai J Med. 2010 Nov-Dec; 77(6):587-96.
      View in: PubMed
    19. Shelton RC, Winkel G, Davis SN, Roberts N, Valdimarsdottir H, Hall SJ, Thompson HS. Validation of the group-based medical mistrust scale among urban black men. J Gen Intern Med. 2010 Jun; 25(6):549-55.
      View in: PubMed
    20. Davis SN, Diefenbach MA, Valdimarsdottir H, Chen T, Hall SJ, Thompson HS. Pros and cons of prostate cancer screening: associations with screening knowledge and attitudes among urban African American men. J Natl Med Assoc. 2010 Mar; 102(3):174-82.
      View in: PubMed
    21. Stock RG, Yalamanchi S, Yamalachi S, Hall SJ, Stone NN. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. J Urol. 2010 Feb; 183(2):546-50.
      View in: PubMed
    22. Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int. 2009 Dec; 104(11):1631-6.
      View in: PubMed
    23. Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest. 2008 Aug; 118(8):2711-21.
      View in: PubMed
    24. Ip C, Hall SJ. Hormonal implications in the development and treatment of prostate cancer. Endocrinol Metab Clin North Am. 2007 Jun; 36(2):421-34.
      View in: PubMed
    25. Jandorf L, Chang MS, Smith K, Florio A, Hall SJ. Community-based free prostate cancer screening program. Prog Community Health Partnersh. 2007; 1(3):215-20.
      View in: PubMed
    26. Stanizzi MA, Hall SJ. Clinical experience with gene therapy for the treatment of prostate cancer. Rev Urol. 2007; 9 Suppl 1:S20-8.
      View in: PubMed
    27. Schnur JB, DiLorenzo TA, Montgomery GH, Erblich J, Winkel G, Hall SJ, Bovbjerg DH. Perceived risk and worry about prostate cancer: a proposed conceptual model. Behav Med. 2006; 32(3):89-96.
      View in: PubMed
    28. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005 Oct 1; 65(19):9080-8.
      View in: PubMed
    29. Cardozo CP, Michaud C, Ost MC, Fliss AE, Yang E, Patterson C, Hall SJ, Caplan AJ. C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch Biochem Biophys. 2003 Feb 1; 410(1):134-40.
      View in: PubMed
    30. Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC, Chen SH, Hall SJ. IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther. 2003 Feb; 7(2):185-92.
      View in: PubMed
    31. Hall SJ, Canfield SE, Yan Y, Hassen W, Selleck WA, Chen SH. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. Gene Ther. 2002 Apr; 9(8):511-7.
      View in: PubMed
    32. Sanford MA, Yan Y, Canfield SE, Hassan W, Selleck WA, Atkinson G, Chen SH, Hall SJ. Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. Hum Gene Ther. 2001 Aug 10; 12(12):1485-98.
      View in: PubMed
    33. Anello R, Cohen S, Atkinson G, Hall SJ. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation. J Urol. 2000 Dec; 164(6):2173-7.
      View in: PubMed
    34. Hall SJ, Bar-Chama N, Ta S, Gordon JW. Direct exposure of mouse spermatogenic cells to high doses of adenovirus gene therapy vector does not result in germ cell transduction. Hum Gene Ther. 2000 Aug 10; 11(12):1705-12.
      View in: PubMed
    35. Hassan W, Sanford MA, Woo SL, Chen SH, Hall SJ. Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. World J Urol. 2000 Apr; 18(2):130-5.
      View in: PubMed
    36. Atkinson G, Hall SJ. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology. 1999 Dec; 54(6):1098-104.
      View in: PubMed
    37. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 1998 Aug 1; 58(15):3221-5.
      View in: PubMed
    38. Hall SJ, Chen SH, Woo SL. The promise and reality of cancer gene therapy. Am J Hum Genet. 1997 Oct; 61(4):785-9.
      View in: PubMed
    Hall's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067